Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA) announced its participation in the Oppenheimer Rare & Orphan Disease Virtual Summit scheduled for May 21, 2021, at 12:25 PM ET. The management will present information about the company's focus on rare respiratory diseases, particularly its lead program, molgramostim nebulizer solution, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Interested parties can access the live audio webcast on Savara's website.

Archived presentations will be available for 90 days following the event.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT.

Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005222/en/

FAQ

What is Savara Inc. presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on May 21, 2021?

Savara Inc. will present information about its focus on rare respiratory diseases and its lead program, molgramostim nebulizer solution, which is in Phase 3 for autoimmune pulmonary alveolar proteinosis (aPAP).

What time is Savara Inc.'s presentation at the Oppenheimer Summit?

Savara Inc.'s presentation is scheduled for May 21, 2021, at 12:25 PM ET.

How can I access Savara Inc.'s presentation at the Oppenheimer Summit?

You can access the live audio webcast of Savara Inc.'s presentation on their Investors page at www.savarapharma.com.

Will the presentation by Savara Inc. be available after the event?

Yes, an archived version of the presentation will be available on Savara's website for 90 days after the event.

What is molgramostim nebulizer solution being developed for?

Molgramostim nebulizer solution is being developed for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).